MDT Stock Recent News

Dividend aristocrat stocks have largely done well in the past few years. The closely-followed ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has jumped by over 133% from its lowest level in 2020.

NEW HOPE, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the appointment of Christopher Cleary to its Board of Directors as an independent member, effective as of January 30, 2025. Mr. Cleary brings over three decades of experience in corporate development, mergers, acquisitions, strategic investments and structured R&D collaborations, having significantly impacted the medical technology industry through his strategic leadership and visionary approach.

Medtronic said on Monday it will appoint Renault's finance chief Thierry Piéton as its Chief Financial Officer, effective March 3.

European approval introduces the world's only closed-loop DBS system with real-time, self-adjusting brain stimulation for people with Parkinson's disease GALWAY, Ireland , Jan. 13, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, announced today CE (Conformité Européenne) Mark approval in the European Union (EU) and the United Kingdom (UK) for BrainSense™ Adaptive deep brain stimulation (aDBS) and BrainSense™ Electrode Identifier (EI), having achieved the standards required by the EU Medical Device Regulation (MDR). In addition, the first programming was completed today, performed by Martijn Beudel, MD, PhD, neurologist and associate professor, Department of Neurology, Amsterdam University Medical Center.

Medtronic remains an attractive investment due to its diversified revenue streams, robust product pipeline and improving margins. MDT's growth is driven by strong performance in Neuroscience, Cardiovascular, and Diabetes care, with significant international revenue growth and a promising product pipeline. Trading below its historical valuation, MDT offers a compelling opportunity for conservative investors seeking quality at a reasonably low price.

The latest rate cut should help Medtronic expand in the AFib, structural heart, robotics, neuromodulation, hypertension and diabetes markets.

Investors continue to be optimistic about Medtronic due to strength in its Neurosurgery portfolio. Yet, mounting expenses pose a threat to the company's margins.

Medtronic plc (NYSE:MDT ) 2024 Wells Fargo Healthcare Conference September 4, 2024 11:35 AM ET Company Participants Geoff Martha - Chairman & CEO Conference Call Participants Larry Biegelsen - Wells Fargo Larry Biegelsen Good afternoon or good morning, and it's about to be good afternoon and welcome to the 2024 Wells Fargo Healthcare Conference. Thank you for helping make this our largest healthcare conference yet.

Geoff Martha, Medtronic CEO, joins 'Money Movers' to discuss the company's quarterly earnings results, where the company's business is toughest, and much more.

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 50 points on Tuesday.